Kyverna Therapeutics (KYTX) CTO Mayobanex Pujols reports no share ownership on Form 3

Rhea-AI Filing Summary

Kyverna Therapeutics, Inc. executive Mayobanex Pujols, the company’s Chief Technology Officer, filed an initial ownership report on Form 3. The filing states that no securities of Kyverna Therapeutics, Inc. are beneficially owned by the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 02/11/2026 - 04:30 PM Learn about SEC filing dates

FAQ

What does the Kyverna Therapeutics (KYTX) Form 3 filing report?

The Form 3 reports initial insider ownership for Chief Technology Officer Mayobanex Pujols. The filing states that no securities of Kyverna Therapeutics, Inc. are beneficially owned, meaning the officer reports holding no KYTX shares or derivative securities at this time.

Who is the reporting person in the Kyverna Therapeutics (KYTX) Form 3?

The reporting person is Mayobanex Pujols, who serves as Chief Technology Officer of Kyverna Therapeutics, Inc. The Form 3 identifies this executive role and confirms that the filing is made by one reporting person, not a group or joint filers.

Does the Kyverna Therapeutics (KYTX) Form 3 show any shares owned?

No, the filing states that no securities are beneficially owned. The explanation of responses section explicitly notes that no securities of Kyverna Therapeutics, Inc. are beneficially owned by the reporting person, covering both non-derivative and derivative securities tables.

What insider role is disclosed in the Kyverna Therapeutics (KYTX) Form 3?

The filing identifies the insider as an officer, specifically the Chief Technology Officer of Kyverna Therapeutics, Inc. This role is marked in the relationship section, while boxes for director and 10% owner are not selected in the ownership relationship checklist.

Is the Kyverna Therapeutics (KYTX) Form 3 an amendment or an initial filing?

This is an initial Form 3 filing, not marked as an amendment. The amendment date field is left blank, and the form is labeled as filed by one reporting person, indicating a standard initial ownership report for the executive insider.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Pujols Mayobanex

(Last) (First) (Middle)

C/O KYVERNA THERAPEUTICS, INC.

5980 HORTON ST., STE 550

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/09/2026

3. Issuer Name and Ticker or Trading Symbol
Kyverna Therapeutics, Inc. [ KYTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Marc Grasso, as Attorney-in-Fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.